Loading organizations...
Science Angel Syndicate functions as an angel investment group, specializing in early-stage scientific startups born from groundbreaking discoveries. It targets disruptive technologies across biology, chemistry, physics, and computer science, aligning investments with Industry 5.0 advancements. The syndicate employs a collective intelligence model, leveraging member expertise for rigorous scientific and commercial due diligence.
Dr. Johnathan Matlock and Dr. Ben Miles founded the syndicate in 2021 in Bristol, UK. Their prior collaboration at Ziylo, a University of Bristol spin-out, highlighted the critical need for specialized support for scientific ventures. This experience inspired their mission to connect scientific innovation with strategic angel capital and expert mentorship.
The syndicate primarily supports startups developing solutions for critical global challenges in health and the environment. It provides capital alongside access to an extensive network of scientific and commercial experts. Their vision is to accelerate commercially viable scientific breakthroughs, translating profound understanding into significant societal impact.
Science Angel Syndicate has 2 tracked investments across 2 companies. The latest tracked deal is $5.1M Seed in MitoRx Therapeutics in December 2023.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Dec 18, 2023 | MitoRx Therapeutics | $5.1M Seed | — | Fink Family Office, Longevity Tech Fund, Oxford Technology Management, Oliver Sexton, Wren Capital |
| Jan 1, 2023 | EnsiliTech | $1.0M Seed | Fink Family Office, Science Angel Syndicate | 7percent Ventures, Elbow Beach Capital, Undeterred Capital, Innovate UK, Qantx |
